Carisbamate

Drug Profile

Carisbamate

Alternative Names: Comfyde; JNJ-10234094; RWJ-333369; YKP-509

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator SK biopharmaceuticals
  • Developer Janssen Research & Development; Johnson & Johnson Pharmaceutical Research & Development; Johnson & Johnson Pharmaceutical Research & Development LLC; Ortho-McNeil Pharmaceutical
  • Class Antiepileptic drugs; Carbamates; Neuroprotectants; Non-opioid analgesics; Small molecules
  • Mechanism of Action Neurotransmitter modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Infantile spasms
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic neuropathies; Epilepsy; Essential tremor; Migraine; Postherpetic neuralgia

Most Recent Events

  • 23 Apr 2012 Carisbamate receives Orphan Drug status for Infantile spasms in USA
  • 01 Aug 2010 Johnson & Johnson completes a phase III trial in patients with partial onset seizures (adjunctive treatment) in USA
  • 17 Apr 2010 Adverse events data from 3 phase I trials in Healthy volunteers presented at the 62nd Annual Meeting of the American Academy of Neurology (AAN-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top